One financial backer invested $250,000 in return for unregistered equity securities issued by Embolx. The transaction completed on February 21st via a non-brokered private placement. No offering was previously initiated by the company under a registration exemption with the SEC.
The company developed and commercializes a highly targeted delivery systems for tumor embolization (nonsurgical, minimally invasive procedure to block blood vessels). It enables oncologists and radiologists to deliver precise doses of drug directly into the tumor vasculature. The technique shows superior clinical outcomes and low toxicity for certain cancers according to the company.
Michael P Allen (President and CEO) leads the Los Altos CA based company which was registered in 2013. No revenues were reported by the company.
The executive team includes Robert J De Neve.
The board of directors includes Paul F Rogan.
Amount offered: $250,000
Amount placed: $250,000
First sale: 02-21-2014
Data as of: 03-07-2014